SEARCH

SEARCH BY CITATION

References

  • 1
    Therrien M., Chang H.C., Solomon N.M., Karim F.D., Wassarman D.A., Rubin G.M. (1995) KSR, a novel protein kinase required for RAS signal transduction. Cell;83:879888.
  • 2
    Sundaram M., Han M. (1995) The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell;83:889901.
  • 3
    Clape ron A., Therrien M. (2007) KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene;26:31433158.
  • 4
    Ray L.B., Sturgill T.W. (1987) Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro. Proc Natl Acad Sci USA;84:15021506.
  • 5
    Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E., Morgenbesser S.D., DePinho R.A., Panayotatos N., Cobb M.H., Yancopoulos G.D. (1991) ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell;65:663675.
  • 6
    Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-I S., Wada H., Fujimoto J., Kohno M. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene;18:813822.
  • 7
    Eblen S.T., Slack J.K., Weber M.J., Catling A.D. (2002) Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol;22:60236033.
  • 8
    Wu X., Noh S.J., Zhou G., Dixon J.E., Guan K.L. (1996) Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem;271:32653271.
  • 9
    Xu S., Khoo S., Dang A., Witt S., Do V., Zhen E., Schaefer E.M., Cobb M.H. (1997) Differential regulation of mitogen-activated protein/ERK kinase MEK1 and MEK2 and activation by a Ras-independent mechanism. Mol Endocrinol;11:16181625.
  • 10
    Catalanotti F., Reyes G., Jesenberger V., Galabova-Kovacs G., de Matos Simoes R., Carugo O., Baccarini M. (2009) A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol;16:294303.
  • 11
    Mody N., Leitch J., Armstrong C., Dixon J., Cohen P. (2001) Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett;502:2124.
  • 12
    Kamakura S., Moriguchi T., Nishida E. (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem;274:2656326571.
  • 13
    Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C. et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol;11:11921197.
  • 14
    Frémin C., Meloche S. (2010) From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol;3:8.
  • 15
    Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., Becelaere K.V., Herrera R., Sebolt-Leopold J., Meyer M.B. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol;23:52815293.
  • 16
    Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., Hanson L.J., Gore L., Chow L., Leong S. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small molecule mitogen-activated protein kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol;26:21392146.
  • 17
    Balagula Y., Barth Huston K., Busam K.J., Lacouture M.E., Chapman P.B., Myskowski P.L. (2011) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs;29:11141121.
  • 18
    Cramer R.D. III, Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA).1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:59595967.
  • 19
    Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem;37:41304146.
  • 20
    Cramer R.D. III, Bunce J.D., Patterson D.E., Frank I.E. (1988) Cross validation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat;7:1825.
  • 21
    Yang G.F., Lu H.T., Xiong Y., Zhan C.G. (2006) Understanding the structure activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses. Bioorg Med Chem;14:14621473.
  • 22
    Jones G., Willett P., Glen R.C. (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol;245:4353.
  • 23
    Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol;267:727748.
  • 24
    El Abdellaoui H., Varaprasad C.V., Barawkar D., Chakravarty S., Maderna A., Tam R., Chen H. et al. (2006) Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett;16:55615566.
  • 25
    Varaprasad C.V., Barawkar D., El Abdellaoui H., Chakravarty S., Allan M., Chen H., Zhang W., Wu J.Z., Tam R., Hamatake R., Lang S., Hong Z. (2006) Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett;16:39753980.
  • 26
    Folkers G., Rognan D., Merz A. (1993) Scope and limitations of CoMFA. In: Kubinyi H., editor. 3D QSAR in Drug Design, Theory, Methods and Application. Leiden: ESCOM Science Publishers B.V; p. 583618.
  • 27
    Viswanadhan V.N., Ghose A.K., Revankar G.R., Robins R.K. (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure- activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci;29:163172.
  • 28
    Kamath S., Buolamwini J.K. (2003) Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem;46:46574668.
  • 29
    Bohm M., Sturzebecher J., Klebe G. (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem;42:458477.
  • 30
    Clark M., Cramer R.D. III (1993) The probability of chance correlation using partial least squares (PLS). Quant Struct Act Relat;12:137145.
  • 31
    Wold S., Ruhe A., Wold H., Dunn W.J. (1984) The collinearity problem in linear regression.The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Comput;5:735743.
  • 32
    Bush B.L., Nachbar R.B. Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des;7:587619.
  • 33
    Roy P.P., Roy K. (2008) On some aspects of variable selection forpartial least squares regression models. QSAR Comb Sci;27:302313.
  • 34
    Iverson C., Larson G., Lai C., Yeh L.T., Dadson C., Weingarten P., Appleby T., Vo T., Maderna A., Vernier J.M., Hamatake R., Miner J.N., Quart B. (2009) RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res;69:68396847.
  • 35
    Tanneeru K., Reddy B.M., Guruprasad L. (2011) Three-dimensional quantitative structure–activity relationship (3D-QSAR) analysis and molecular docking of ATP-competitive triazine analogs of human mTOR inhibitors. Med Chem Res; doi: 10.1007/s00044-011-9629-x.
  • 36
    Tanneeru K., Guruprasad L. (2011) Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J Mol Model; doi: 10.1007/s00894-011-1184-3.
  • 37
    QSAR (1993) Hansch analysis and related approaches. In: Mannhold R., Kroogsgrad-Larsen P., Timmerman H., editors. Methods and Principles in Medicinal Chemistry, Vol. 1. Weinheim: VCH; p. 91–107.